Stockreport

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Galmed Pharmaceuticals Ltd. - Ordinary Shares  (GLMD) 
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: galmedpharma.investorroom.com
PDF 98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS).Galmed has developed, [Read more]